|
Phillips, R M; Naylor, M A; Jaffar, M et al. (1999) Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. J Med Chem 42:4071-80
|
|
Siemann, D W; Hinchman, C A (1998) Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiother Oncol 47:215-20
|
|
Jaffar, M; Naylor, M A; Robertson, N et al. (1998) 5-substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop-2-en- 1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: structure-cytotoxicity in vitro. Anticancer Drug Des 13:105-23
|
|
Dachs, G U; Patterson, A V; Firth, J D et al. (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3:515-20
|
|
Butler, S A; Wood, P J; Cole, S et al. (1997) Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase. Br J Cancer 76:438-44
|
|
Patterson, A V; Saunders, M P; Chinje, E C et al. (1997) Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76:1338-47
|
|
Naylor, M A; Jaffar, M; Nolan, J et al. (1997) 2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. J Med Chem 40:2335-46
|
|
Moody, C J; Roffey, J R; Stephens, M A et al. (1997) Synthesis and cytotoxic activity of indolyl thiazoles. Anticancer Drugs 8:489-99
|
|
Siemann, D W (1996) The in situ tumour response to combinations of cyclophosphamide and tirapazamine. Br J Cancer Suppl 27:S65-9
|
|
Barham, H M; Inglis, R; Chinje, E C et al. (1996) Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells. Br J Cancer 74:1188-93
|
Showing the most recent 10 out of 24 publications
